Scientific Program - Machado Joseph Disease (MJD/SCA3)

Print
Please see below the CONy Scientific Program. Please click on the appropriate section to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable / overview, please click here
 
For the full Scientific Program, please click here >
Orient Foundation Museum: Pre-congress activity day (not for CME)
THURSDAY, MARCH 17, 2016
HALL B
11:00-13:15
MJD: FROM CLINICAL FEATURES TO GENE AND PROTEIN
Chairs: Luis Pereira de Almeida, Portugal; Thomas Klockgether, Germany
11:00-11:15
Introductory remarks
Luis Pereira de Almeida, Portugal; Thomas Klockgether, Germany
 
11:15-12:15 Clinical perspective
11:15-11:30
11:30-11:45
11:45-12:00
12:00-12:15
Clinical features and the natural history: Thomas Klockgether, Germany
Clinical features | Central Portugal Cohort: Cristina Januario, Portugal
MRI imaging: Marcondes França, Brazil
Executive impairment correlates with motor impairment in SCA-3: Michael Geschwind, USA
12:15-13:15 ATXN3 gene and protein
12:15-12:30
12:30-12:45
12:45-13:00
13:00-13:15
Ancestral origins of MJD/SCA-3: Sandra Martins, Portugal
Planning and feasibility of clinical trials: Thomas Klockgether, Germany
Ataxin-3 structure and function: Sandra Macedo-Ribeiro, Portugal
Phosphorylation of ataxin-3: Ana Luisa Carvalho, Portugal
13:15-14:00 Lunch Break
14:00-16:30
MODELS AND MECHANISMS OF DISEASE
14:00-15:15 Models of disease
14:00-14:15 C. Elegans: Andreia Teixeira-Castro, Portugal
14:15-14:30 Potential treatment on MJD/SCA-3 drosophila models and patients: Hong Jiang, China
14:30-14:45
Zebrafish model of MJD: Mainne Watchon, Australia
14:45-15:00
Knock-in model of MJD/SCA-3: Maciej Figiel, Poland
15:15-16:30 Mechanisms of disease
15:15-15:30
15:30-15:45
15:45-16:00
16:00-16:15
16:15-16:30
Nuclear localization and transport: Thorsten Schmidt, Germany
DNA-repair mechanisms: Partha Sarkar, USA
Transcriptional dysregulation: Bernd Evert, Germany
Regulation of translation of Ataxin-3 by Ataxin-2: Clevio Nobrega, Portugal
Proteolysis of ataxin-3: Jonasz Weber, Germany
16:30-17:30
FROM PRE-CLINICAL STUDIES TO CLINICAL TRIALS
16:30-17:30 Pharmacological and advancedtherapies
16:30-16:45
16:45-17:00
17:00-17:15
17:15-17:30
Low molecular weight drugs: Patrícia Maciel, Portugal
Pre-clinical studies with trehalose: Magda Santana, Portugal
Stem cell therapies: Liliana Mendonça, Portugal
Molecular approaches for MJD: Luis Pereira de Almeida, Portugal
17:30-18:30 Cinical trials
17:30-17:45
17:45-18:00
18:00-18:15
Biomarkers of MJD/SCA-3: Manuela Lima, Portugal
The Lithium clinical trial: Laura Jardim, Brazil
Preliminary results of intravenous trehalose for the treatment of SCA3: Carlos Gordon, Israel
18:15-18:30
Closing remarks and discussion
Luis Pereira de Almeida, Portugal; Thomas Klockgether, Germany
Details to follow. Please submit your abstract directly to the CONy Secretariat: cony@comtecmed.com